Predict your next investment

Corporation
HEALTHCARE | Drug Development
merck.com

See what CB Insights has to offer

Investments

20

Portfolio Exits

21

Partners & Customers

10

About Merck & Co.

Merck & Co. (NYSE: MRK) is a global healthcare company. Through its prescription medicines, vaccines, biologic therapies, and animal health products, the company works with customers and operates in more than 140 countries to deliver health solutions. Merck & Co. was originally a subsidiary of Merck Group before becoming independent in 1917.

Merck & Co. Headquarter Location

2000 Galloping Hill Road

Kenilworth, New Jersey, 07033,

United States

908-740-4000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Merck & Co.

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Merck & Co. in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

Merck & Co. Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Merck & Co. Rank

Research containing Merck & Co.

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Merck & Co. in 4 CB Insights research briefs, most recently on May 5, 2021.

Latest Merck & Co. News

U.S. FDA advisers to review Merck’s oral COVID-19 drug next month

Oct 15, 2021

Reuters / 06:39 AM October 15, 2021 The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. (REUTERS/file photo) A panel of outside advisers to the U.S. health regulator will meet late next month to discuss whether to authorize Merck & Co’s experimental COVID-19 antiviral drug, the agency said on Thursday. The U.S. Food and Drug Administration’s (FDA) panel will meet on Nov. 30 to discuss safety and effectiveness of the drug, molnupiravir, for the treatment of mild-to-moderate COVID-19 in adults who have tested positive and are at high risk for progression to severe illness. ADVERTISEMENT The FDA typically follows the advice of its experts but is not bound to do so. Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir, which it is developing with partner Ridgeback Biotherapeutics. The drug would become the first oral antiviral medication for COVID-19, if cleared by the agency. FEATURED STORIES Pfizer Inc and Swiss drugmaker Roche Holding AG are also racing to develop an easy-to-administer antiviral pill for the disease. Merck’s treatment cut the rate of hospitalization and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released earlier this month. The company has a contract with the U.S. government to supply 1.7 million courses at a price of $700 per course. The drugmaker also recently signed deals with Malaysia and Singapore for supply of the drug. Bloomberg News first reported on a U.S. FDA advisory committee review of the drug. gsg Subscribe to our daily newsletter By providing an email address. I agree to the Terms of Use andacknowledge that I have read the Privacy Policy . For more news about the novel coronavirus click here. For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150. The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link . Read Next

Merck & Co. Investments

20 Investments

Merck & Co. has made 20 investments. Their latest investment was in Seattle Genetics as part of their Corporate Minority - P2P on September 9, 2020.

CBI Logo

Merck & Co. Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/14/2020

Corporate Minority - P2P

Seattle Genetics

$1,000M

Yes

8

7/17/2020

Series B

SAB Biotherapeutics

$14M

Yes

South Dakota Equity Partners, and Undisclosed Investors

5

6/29/2020

Series C

Yumanity Therapeutics

$21.62M

Yes

3

3/2/2020

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

4/18/2019

Milestone Payment

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/14/2020

7/17/2020

6/29/2020

3/2/2020

4/18/2019

Round

Corporate Minority - P2P

Series B

Series C

Unattributed

Milestone Payment

Company

Seattle Genetics

SAB Biotherapeutics

Yumanity Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$1,000M

$14M

$21.62M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

South Dakota Equity Partners, and Undisclosed Investors

Sources

8

5

3

10

10

Merck & Co. Portfolio Exits

21 Portfolio Exits

Merck & Co. has 21 portfolio exits. Their latest portfolio exit was SAB Biotherapeutics on June 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/22/2021

Acq - Pending

$991

2

3/22/2021

Acquired

$991

10

9/21/2020

Acquired

$991

18

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

6/22/2021

3/22/2021

9/21/2020

00/00/0000

00/00/0000

Exit

Acq - Pending

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

10

18

10

10

Merck & Co. Acquisitions

39 Acquisitions

Merck & Co. acquired 39 companies. Their latest acquisition was Acceleron Pharma on September 30, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/30/2021

PIPE

$991

$136.52M

Acq - Pending

5

6/3/2021

Acquired - II

Spinoff / Spinout

2

4/1/2021

IPO

$991

$138M

Acq - P2P

18

11/23/2020

Series B

Subscribe to see more

$991

$99M

Subscribe to see more

10

11/5/2020

Series B

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

9/30/2021

6/3/2021

4/1/2021

11/23/2020

11/5/2020

Investment Stage

PIPE

Acquired - II

IPO

Series B

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Total Funding

$136.52M

$138M

$99M

$99M

Note

Acq - Pending

Spinoff / Spinout

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

5

2

18

10

10

Merck & Co. Partners & Customers

10 Partners and customers

Merck & Co. has 10 strategic partners and customers. Merck & Co. recently partnered with f-star Biotechnology on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/4/2021

Partner

f-star Biotechnology

Austria

1

7/29/2021

Partner

Bayer

Germany

1

7/9/2021

Partner

Rigebackbio

United States

Merck Statement on Clinical Data for Molnupiravir Generated by Hetero in India - Merck.com

Merck & Co. , Inc. is developing molnupiravir in collaboration with Ridgeback Biotherapeutics .

3

6/30/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/30/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/4/2021

7/29/2021

7/9/2021

6/30/2021

6/30/2021

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

f-star Biotechnology

Bayer

Rigebackbio

Country

Austria

Germany

United States

Subscribe to see more

Subscribe to see more

News Snippet

Merck Statement on Clinical Data for Molnupiravir Generated by Hetero in India - Merck.com

Merck & Co. , Inc. is developing molnupiravir in collaboration with Ridgeback Biotherapeutics .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

3

10

10

Merck & Co. Team

80 Team Members

Merck & Co. has 80 team members, including current Chief Executive Officer, Kenneth C Frazier.

Name

Work History

Title

Status

Kenneth C Frazier

Chief Executive Officer

Current

Sanat Chattopadhyay

President, Executive Vice President

Current

Frank Clyburn

President, Executive Vice President

Current

Robert M. Davis

President

Current

Jannie Oosthuizen

President

Current

Name

Kenneth C Frazier

Sanat Chattopadhyay

Frank Clyburn

Robert M. Davis

Jannie Oosthuizen

Work History

Title

Chief Executive Officer

President, Executive Vice President

President, Executive Vice President

President

President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.